anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To evaluate differences in auxological parameters between transgender and cisgender adolescents.
METHODS: Retrospective analysis of auxological data of 269 transgender and gender diverse patients (75% assigned female at birth or AFAB, 25% assigned male at birth or AMAB) at the outpatient clinic for Pediatric Endocrinology at the Vienna General Hospital. All were treatment naïve at initial measurement. Height and weight data were compared to current World Health Organization (WHO) standards, defining a standard deviation score (SDS) of ≥ 1 ≤ 2 as overweight and > 2 as obese.
RESULTS: In our untreated transgender population (mean age 15.7 years), 20% were overweight and 17% obese. Mean BMI was 0.64 SDS above the WHO average (p < .001). This result was more pronounced in the AFAB subgroup (+0.73 SDS, p < .001) than in the AMAB group (+0.37 SDS, p = .07). The AMAB group showed markedly higher BMI variance compared to WHO standards (p < .001) and to the AFAB group (p = .03), due to a higher relative number of underweight observations. When correcting for psychiatric diagnosis, transgender patients were still significantly overweight (p < .001). In patients for whom data both pregender-affirming hormone therapy and during gender-affirming hormone therapy was available (n = 133), BMI SDS did not change significantly over time (p = .22).
DISCUSSION: We observed significantly higher rates of overweight and obesity in our adolescent transgender cohort. The reasons are likely complex and multifactorial. This makes eating and exercise behaviors central in both transgender care and future research.
PROBLEM TO BE SOLVED: To provide an ink for an inkjet printer which enables clear identification of a tablet by printing the name, symbol or the like of the tablet on the tablet surface in order to eliminate a risk of malpractice of mistaking tablets.SOLUTION: The invention provides a tablet having a dry-ink film with which information for enhancing identifiability is printed on a surface of the tablet in which powders on the surface of the tablet are 0.2 wt.% or less of the total weight of the tablet, and an ink for inkjet printer in which a reflection density of the dry film is 0.1-0.3, and hardness of the dry-ink film at the time of drying is from 2B to 4H of pencil hardness. The dry film contains a resin and a pigment. The resin is contained in an amount of 15-30 pts.wt. based on 1 pt.wt. of the pigment. Preferably the resin is shellac and the pigment is carbon dust pigment.
PROBLEM TO BE SOLVED: To obtain a cosmetic effective for the normalization of skin and the prevention of skin injury caused by active oxygen or ultraviolet rays. SOLUTION: This cosmetic contains 0.01-50wt.% each of one or more factors or components selected from among an indigenous skin bacterium proliferation factor (e.g. essential amino acid), a factor inhibiting the growth of harmful skin bacterium (e.g. higher fatty acid) and a nutrient source of indigenous skin bacterium (e.g. skin or sweat component).  The essential amino acid is arginine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine and valine, the higher fatty acid as the proliferation factor is stearic acid and oleic acid, the higher fatty acid as the growth inhibiting factor is lauric acid, myristic acid, palmitoleic acid, linoleic acid, linolenic acid, arachidic acid and arachidonic acid, the sebum component is triglyceride, wax ester, squalene, cholesterol ester and cholesterol and the sweat component is water, chlorine, Na, K, Ca, Mg, N, ammonia, glucose and lactic acid.
A medical fluid delivery system including analytics for managing patient engagement and treatment compliance is disclosed. In an example, an interface device receives treatment data from a dialysis machine for a patient undergoing dialysis. An analytics processor determines dialysis treatment parameter values by comparing the treatment data to a record of a prescribed therapy or program. The dialysis treatment parameter values may include a lost treatment time parameter value, a lost dwell time parameter value, and/or a completed treatment days parameter value. The analytics processor causes the dialysis treatment parameter values to be displayed within a user interface on a clinician device. The dialysis treatment parameter values provide an indication as to how well the patient is complying with the prescribed therapy or program, and may be used by a clinician to help a patient improve compliance if needed.A medical fluid delivery system including analytics for managing patient engagement and treatment compliance is disclosed. In an example, an interface device receives treatment data from a dialysis machine for a patient undergoing dialysis. An analytics processor determines dialysis treatment parameter values by comparing the treatment data to a record of a prescribed therapy or program. The dialysis treatment parameter values may include a lost treatment time parameter value, a lost dwell time parameter value, and/or a completed treatment days parameter value. The analytics processor causes the dialysis treatment parameter values to be displayed within a user interface on a clinician device. The dialysis treatment parameter values provide an indication as to how well the patient is complying with the prescribed therapy or program, and may be used by a clinician to help a patient improve compliance if needed. An airplane rudder and brake pedal assembly includes a rudder arm assembly having one rudder arm with first upper and lower arm portions, and another rudder arm with second upper and lower arm portions. The rudder arm assembly is assembled to a beam at an intersection of the first upper and lower arm portions, and an intersection of the second upper and lower arm portions. The first and second rudder arms are configured to rotate about the beam at the intersection. The rotation of the first and second rudder arms is configured to adjust control surfaces that control a yaw axis of the airplane. A brake pedal is attached to the first and second lower arm portions. Rotation of the brake pedal brakes the airplane. A rotary sensor is assembled to the brake pedal and the lower arm portion, and configured to determine an extent of the brake pedal rotation.
A method for manufacturing Levothyroxin sodium in tablets comprises the preparation of the raw materials, their mixing, drying, granulation and compression. The aqueous suspension of Levothyroxin sodium is added at the room temperature to Hypromellose solution prepared beforehand to produce the stable suspension of Levothyroxin sodium in Hypromellose solution. This suspension is used for moistening lactose and starch (for example, cornstarch). The mixture is granulated. The wet granules are dried and powdered with croscarmellose and magnesium stearate. Finally, the mixture is compressed, and the tablets are produced.
INTRODUCTION: Lateral pelvic node dissection (LPND) poses significant technical challenges. Despite the advent of robotic surgery, determining the optimal minimally invasive approach remains a topic of debate. This study aimed to compare postoperative outcomes between robotic total mesorectal excision with LPND (R-LPND) and laparoscopic total mesorectal excision with LPND (L-LPND).
METHODS: This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 and AMSTAR 2 (Assessing the Methodological Quality of Systematic Reviews) guidelines. Utilizing the RevMan 5.3.5 statistical package from the Cochrane Collaboration, a random-effects model was employed.
RESULTS: Six eligible studies involving 652 patients (316 and 336 in the R-LPND and L-LPND groups, respectively) were retrieved. The robotic approach demonstrated favourable outcomes compared with the laparoscopic approach, manifesting in lower morbidity rates, reduced urinary complications, shorter hospital stays, and a higher number of harvested lateral pelvic lymph nodes. However, longer operative time was associated with the robotic approach. No significant differences were observed between the two groups regarding major complications, anastomotic leak, intra-abdominal infection, neurological complications, LPND time, overall recurrence, and local recurrence.
CONCLUSIONS: In summary, the robotic approach is a safe and feasible alternative for Total Mesorectal Excision (TME) with LPND in advanced rectal cancer. Notably, it is associated with lower morbidity, particularly a reduction in urinary complications, a shorter hospital stay and increased number of harvested lateral pelvic nodes. The trade-off for these benefits is a longer operative time.
PURPOSE: To prepare an oligonucleotide used as diagnostics for the detection of diseases caused by the infection of virus or genes.  
     CONSTITUTION: The compd. in the form of racemate or enantiomer of a compd. of formula I (R 1  and R 2  are H or a protecting group; B is purine, pyrimidine or the anologue thereof). The compd. is obtd. by bringing a compd. in the form of racemate or enantiomer of a compd. of formula II (R 14  and R 15  are a protecting group; X is an elimlnable group) to react with purine, the analogues of purine of the anologues of pyrimidine at -20 to 150°C, preferably, at 0 to 100°C in an aprotic solvent and eliminating the protecting group if need. For preparing oligonucleotide having the same or different monomer unit of the compd. of the formula I or the monomer unit of the other nucleotide by 2 to 200 pieces, preferably, 2 to 20 pieces, the compd. of the formula I is used. The compd. in which both R 1  and R 2  are H has antiviral and antiproductive action and can be used as medicines. 
     COPYRIGHT: (C)1993,JPO
BACKGROUND: While the pericapsular nerve group (PENG) block has become increasingly popular for managing pain after hip surgery, its efficacy remains controversial.
METHODS: We systematically searched Pubmed, Web of Science, Embase, and the Cochrane Library for randomized controlled trials to assess current evidence about the efficacy of the PENG block. Patients who received PENG block were compared to those who received sham/no block in terms of opioid consumption and pain within 24h after surgery, time to first opioid requirement, functional recovery, risk of nausea and vomiting, and patient dissatisfaction. The quality of evidence was assessed using the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) system.
RESULTS: We meta-analyzed six trials involving 416 patients who received preoperative PENG block and 415 who received sham/no block. Patients did not receive any other type of multimodal analgesia. Within 24 h after hip surgery, PENG block significantly reduced postoperative opioid consumption (MD = -12.03, 95% CI: -21.47 to -2.59, P < 0.01, I2 = 97%), particularly in subpopulations undergoing hip replacement, hip fracture, or who had spinal anesthesia, and it significantly decreased dynamic pain scores, but not static scores, without increasing risk of nausea or vomiting or patient dissatisfaction. Individual studies suggested that the PENG block can prolong the time to the first opioid requirement and can improve functional recovery. Most meta-analyses provided evidence of moderate quality according to the GRADE system.
CONCLUSIONS: The available evidence indicates that preoperative PENG block can significantly decrease opioid consumption and pain early after hip surgery, and it may also promote early functional rehabilitation. However, the limited number of included studies and sample size make it difficult to draw firm conclusions. The decision on whether to apply the PENG block should take into account the patient's age and the type of surgery and anesthesia.
XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
Subjects have histologically confirmed WHO gr IV primary malignant glioma that is unresectable/multifocal. This is Phase II study where up to 41 subjects will receive up to 4 cycles of Avastin \& Temozolomide. Avastin administered at 10 mg/kg every 14 days beginning a minimum of 7 days after biopsy/28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in 28-day cycle. Patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT. Study will use 2-stage "minimax" study design in which 21 subjects are accrued during 1st stage, with possibility that additional 20 patients accrued during 2nd stage. In initial Phase I \& II trials, 4 potential Avastin-associated safety signals were identified: hypertension, proteinuria, thromboembolic events, \& hemorrhage. Avastin-associated adverse events in Phase III trials include congestive heart failure, GI perforations, wound healing complications, \& arterial thromboembolic events. Most common toxicity associated with Temozolomide has been mild myelosuppression.
Methods for treating carpal tunnel syndrome and tarsal tunnel syndrome in a subject involve providing an effective amount of an anti-cytokine agent at or near inflammation in the carpal or tarsal tunnel. Anti-cytokine agents, such as, TNF-a inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors, IL-10, Interferon-gamma (IFN-?) act to prevent further inflammation initiated by cytokine factors. One embodiment includes, adding with the anti-cytokine agent one or more of an antibiotic or analgesic. Delivery of the anti-cytokine agent may be provided to the inflamed tissue of the carpal or tarsal tunnel by injection, implantation, or a transdermal patch. These agents, individually or in combination, directly address the underlying inflammation that causes the discomfort, pain, and restricted movement associated with carpal and tarsal tunnel syndrome.
BACKGROUND: Intraoperative hypothermia is a common complication during cesarean section (C-section) and associated with the high maternal mortality and morbidity. This study aimed to explore the risk factors associated with the incidence of intraoperative hypothermia in women who underwent emergency C-section deliveries.
METHODS: We retrospectively enrolled women who underwent emergency cesarean deliveries from August 2022 to Dec 2023 at Suzhou Municipal Hospital of Anhui Province. Baseline characteristics, thermal status, and perioperative information were extracted. Hypothermia was defined as the onset of a core temperature below 36 °C. Data were compared between patients with and without a hypothermia during surgery. Logistic regression analyses were performed to determine the risk factors for low-temperature-status.
RESULTS: Overall, 87 patients were included, and 30 underwent hypothermia during surgery. For women with a normal temperature status, women in the hypothermia group had a lower incidence of receiving active warming methods (52.6% vs. 30%, P = 0.044). In the logistic regression model involving core temperature, a pre-surgery core temperature < 36.5 °C (OR 4.22, 95% CI 1.13-15.63, p = 0.032) and a long surgery duration (per 10 min, OR 1.97, 95% CI 1.24-3.11, p = 0.004) were associated with a high probability of hypothermia. Administering active warming methods to women can reduce the risk of experiencing a hypothermia during emergency C-sections (OR 0.19, 95% CI 0.05-0.63; p = 0.007).
CONCLUSIONS: Hypothermia is common in emergency C-section deliveries. It is recommended that active warming methods should be applied to parturient undergoing emergency C-sections more proactively, especially for women who have a low baseline core temperature (< 36.5 °C) and are expected to have a long surgery duration.
Frontotemporal lobe abnormalities are linked to neuropsychiatric disorders and cognition, but the role of cellular heterogeneity between temporal lobe (TL) and frontal lobe (FL) in the vulnerability to genetic risk factors remains to be elucidated. We integrated single-nucleus transcriptome analysis in 'fresh' human FL and TL with genetic susceptibility, gene dysregulation in neuropsychiatric disease and psychoactive drug response data. We show how intrinsic differences between TL and FL contribute to the vulnerability of specific cell types to both genetic risk factors and psychoactive drugs. Neuronal populations, specifically PVALB neurons, were most highly vulnerable to genetic risk factors for psychiatric disease. These psychiatric disease-associated genes were mostly upregulated in the TL, and dysregulated in the brain of patients with obsessive-compulsive disorder, bipolar disorder and schizophrenia. Among these genes, GRIN2A and SLC12A5, implicated in schizophrenia and bipolar disorder, were significantly upregulated in TL PVALB neurons and in psychiatric disease patients' brain. PVALB neurons from the TL were twofold more vulnerable to psychoactive drugs than to genetic risk factors, showing the influence and specificity of frontotemporal lobe differences on cell vulnerabilities. These studies provide a cell type resolved map of the impact of brain regional differences on cell type vulnerabilities in neuropsychiatric disorders.
After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
Described is a GBD-SSTad-SSTad recombinant protein and a method for producing same on a glucan, which includes binding a GBD-SSTad-SSTad protein contained in cell extracts of E. coli strain BL21 [pGBD-SSTad-SSTad] with an alpha glycan-containing sorbent by affinity interaction during an incubation process, subsequently washing off unbound bacterial proteins, and isolating the target product. The protein produced is used to increase mature follicle count and to improve sperm quality indices by means of the KNFFWKTFTS peptide contained in the recombinant protein, which is capable of forming autoantibodies to somatostatin, in other words the protein can be used to treat male and female infertility. The protein produced is immunologically active and easy to purify. The recombinant protein includes two antigenic determinants of somatostatin and a glucan-binding domain. Proposed is a method for producing the target protein on a glucan, which involves binding the protein with a glucan-containing sorbent by affinity interaction, subsequently washing off unbound bacterial proteins, and isolating the target product. An injectable drug produced on the basis of the claimed protein is suitable for subcutaneous or intramuscular injection.
Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 70% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
Functional constipation is a common problem which affects over 3% of children. The standard treatment does not provide sustained relief of symptoms. As a consequence, there is interest in other therapeutic options. Previously, one small (n=40) randomized controlled trial (RCT) involving 27 children showed that Lactobacillus rhamnosus casei Lcr35 compared with placebo increased treatment success defined as ≥ 3 spontaneous defecations per week with no episodes of faecal soiling, increased the defecation frequency, reduced the frequency of abdominal pain, reduced the use of glycerin enemas during the four weeks of therapy, and decreased the percentage of hard stools. However, there was no difference between groups in the use of lactulose or the number of episodes of faecal soiling. Available evidence is insufficient to draw meaningful conclusion. Further studies are needed.
Patients visiting an orthopeadic surgeon in one of our 4 affiliated offices in a large urban area in the United States are invited to participate over a 4 month period. All English-speaking patients, between 18 and 89 years old, visiting an orthopeadic surgeon with a new problem, for which either invasive or non-invasive treatment is possible and a DA is available are asked to participate in this study. Exclusion criteria are non-English speakers or a clear preference for a treatment option by surgeon or patient. Patients will be randomly assigned to either the intervention or the control group in a 1:1 ratio using an Excel random number generator. Patients in the intervention group go over the DA during the visit, once the surgeon has identified the diagnosis. After the diagnosis is set, the surgeon steps out of the visit and steps back in when the patients has reviewed the DA. The surgeon and the patient go over the treatment options and a decision will be made. After the visit, all patients, both in the intervention and control group, are asked to fill out a survey. Two weeks after enrollment a research assistant calls all patients for a follow up questionnaire.
This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.